KRAS and non-small cell lung carcinoma: Consistent with this concept, anti-inflammatory therapy with the IL-1β monoclonal antibody canakinumab in NSCLC, which is often driven by KRAS mutations, significantly reduced lung cancer incidence and mortality89.